bioAffinity Technologies (BIAF) EBITDA (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of EBITDA data on file, last reported at -$3.6 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$3.6 million, down 39.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.4 million (down 20.52% YoY), and the FY2025 annual result was -$10.4 million, down 18.33% from the prior year.
• EBITDA eased to -$3.6 million in Q1 2026 per BIAF's latest filing, from -$3.1 million in the prior quarter.
• Over five years, EBITDA peaked at -$684119.0 in Q2 2022 and troughed at -$3.6 million in Q1 2026.
• A 5-year average of -$2.0 million and a median of -$2.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA sank 156.88% in 2023, then increased 14.05% in 2024.
• A 5-year view of EBITDA shows it stood at -$1.6 million in 2022, then slumped by 34.62% to -$2.2 million in 2023, then plunged by 33.44% to -$2.9 million in 2024, then slipped by 6.74% to -$3.1 million in 2025, then slipped by 15.91% to -$3.6 million in 2026.
• Business Quant data shows BIAF's EBITDA at -$3.6 million in Q1 2026, -$3.1 million in Q4 2025, and -$2.2 million in Q3 2025.